Because 0 7 0 7 O
there 8 13 8 13 O
is 14 16 14 16 O
an 17 19 17 19 O
unknown 20 27 20 27 O
but 28 31 28 31 O
potential 32 41 32 41 O
risk 42 46 42 46 O
for 47 50 47 50 O
adverse 51 58 51 58 O
events 59 65 59 65 O
in 66 68 66 68 O
nursing 69 76 69 76 O
infants 77 84 77 84 O
secondary 85 94 85 94 O
to 95 97 95 97 O
treatment 98 107 98 107 B-treatment
of 108 110 108 110 O
the 111 114 111 114 O
mother 115 121 115 121 O
with 122 126 122 126 O
paclitaxel 127 137 127 137 B-treatment
, 137 138 137 138 O
breastfeeding 139 152 139 152 O
should 153 159 153 159 O
be 160 162 160 162 O
discontinued 163 175 163 175 O
if 176 178 176 178 O
the 179 182 179 182 O
mother 183 189 183 189 O
is 190 192 190 192 O
enrolled 193 201 193 201 O
in 202 204 202 204 O
the 205 208 205 208 O
trial 209 214 209 214 O

History 0 7 215 222 O
of 8 10 223 225 O
allergic 11 19 226 234 O
reactions 20 29 235 244 O
attributed 30 40 245 255 O
to 41 43 256 258 O
compounds 44 53 259 268 O
of 54 56 269 271 O
similar 57 64 272 279 O
chemical 65 73 280 288 O
or 74 76 289 291 O
biologic 77 85 292 300 O
composition 86 97 301 312 O
to 98 100 313 315 O
paclitaxel 101 111 316 326 B-allergy_name
including 112 121 327 336 O
to 122 124 337 339 O
other 125 130 340 345 O
drugs 131 136 346 351 O
formulated 137 147 352 362 O
in 148 150 363 365 O
Cremophor(R 151 162 366 377 B-allergy_name
) 162 163 377 378 I-allergy_name
EL 164 166 379 381 I-allergy_name
( 167 168 382 383 I-allergy_name
polyoxyethylated 168 184 383 399 I-allergy_name
castor 185 191 400 406 I-allergy_name
oil 192 195 407 410 I-allergy_name
) 195 196 410 411 I-allergy_name

No 0 2 412 414 O
other 3 8 415 420 O
investigational 9 24 421 436 O
or 25 27 437 439 O
commercial 28 38 440 450 O
therapeutic 39 50 451 462 O
agents 51 57 463 469 O
may 58 61 470 473 O
be 62 64 474 476 O
given 65 70 477 482 O
concurrently 71 83 483 495 O
with 84 88 496 500 O
the 89 92 501 504 O
paclitaxel 93 103 505 515 B-treatment

Patient 0 7 516 523 O
must 8 12 524 528 O
be 13 15 529 531 O
willing 16 23 532 539 O
to 24 26 540 542 O
undergo 27 34 543 550 O
additional 35 45 551 561 O
biopsy 46 52 562 568 B-treatment
of 53 55 569 571 O
breast 56 62 572 578 B-cancer
tumor 63 68 579 584 I-cancer
or 69 71 585 587 O
lymph 72 77 588 593 O
node 78 82 594 598 O

Patients 0 8 599 607 O
must 9 13 608 612 O
be 14 16 613 615 O
candidates 17 27 616 626 O
for 28 31 627 630 O
neoadjuvant 32 43 631 642 B-treatment
paclitaxel 44 54 643 653 I-treatment
chemotherapy 55 67 654 666 I-treatment
by 68 70 667 669 O
their 71 76 670 675 O
treating 77 85 676 684 O
oncologist 86 96 685 695 O

Patients 0 8 696 704 O
must 9 13 705 709 O
not 14 17 710 713 O
have 18 22 714 718 O
metastatic 23 33 719 729 B-cancer
disease 34 41 730 737 I-cancer
on 42 44 738 740 O
staging 45 52 741 748 O
work 53 57 749 753 O
- 57 58 753 754 O
up 58 60 754 756 O
with 61 65 757 761 O
CBC 66 69 762 765 O
and 70 73 766 769 O
liver 74 79 770 775 O
function 80 88 776 784 O
studies 89 96 785 792 O

Patients 0 8 793 801 O
on 9 11 802 804 O
non 12 15 805 808 O
- 15 16 808 809 O
aspirin 16 23 809 816 O
anti 24 28 817 821 O
- 28 29 821 822 O
coagulation 29 40 822 833 O
( 41 42 834 835 O
Coumadin 42 50 835 843 B-treatment
, 50 51 843 844 O
heparins 52 60 845 853 B-treatment
, 60 61 853 854 O
or 62 64 855 857 O
clopidogrel 65 76 858 869 B-treatment
) 76 77 869 870 O
or 78 80 871 873 O
with 81 85 874 878 O
documented 86 96 879 889 O
bleeding 97 105 890 898 B-chronic_disease
disorders 106 115 899 908 I-chronic_disease
will 116 120 909 913 O
be 121 123 914 916 O
excluded 124 132 917 925 O
due 133 136 926 929 O
to 137 139 930 932 O
risk 140 144 933 937 O
of 145 147 938 940 O
bleeding 148 156 941 949 O
with 157 161 950 954 O
biopsy 162 168 955 961 B-treatment

Pregnant 0 8 962 970 B-pregnancy
women 9 14 971 976 B-gender
are 15 18 977 980 O
excluded 19 27 981 989 O
from 28 32 990 994 O
this 33 37 995 999 O
study 38 43 1000 1005 O
because 44 51 1006 1013 O
paclitaxel 52 62 1014 1024 B-treatment
is 63 65 1025 1027 O
a 66 67 1028 1029 O
pregnancy 68 77 1030 1039 B-pregnancy
category 78 86 1040 1048 B-treatment
D 87 88 1049 1050 I-treatment
drug 89 93 1051 1055 I-treatment
and 94 97 1056 1059 O
may 98 101 1060 1063 O
cause 102 107 1064 1069 O
deleterious 108 119 1070 1081 O
effects 120 127 1082 1089 O
to 128 130 1090 1092 O
the 131 134 1093 1096 O
fetus 135 140 1097 1102 O

The 0 3 1103 1106 O
primary 4 11 1107 1114 O
tumor 12 17 1115 1120 B-cancer
must 18 22 1121 1125 O
be 23 25 1126 1128 O
measurable 26 36 1129 1139 O
by 37 39 1140 1142 O
an 40 42 1143 1145 O
imaging 43 50 1146 1153 O
modality 51 59 1154 1162 O
prior 60 65 1163 1168 O
to 66 68 1169 1171 O
treatment 69 78 1172 1181 B-treatment

This 0 4 1182 1186 O
imaging 5 12 1187 1194 O
modality 13 21 1195 1203 O
is 22 24 1204 1206 O
to 25 27 1207 1209 O
be 28 30 1210 1212 O
repeated 31 39 1213 1221 O
after 40 45 1222 1227 O
completion 46 56 1228 1238 O
of 57 59 1239 1241 O
4 60 61 1242 1243 O
cycles 62 68 1244 1250 O
of 69 71 1251 1253 O
paclitaxel 72 82 1254 1264 B-treatment
and 83 86 1265 1268 O
prior 87 92 1269 1274 O
to 93 95 1275 1277 O
surgery 96 103 1278 1285 B-treatment

Women 0 5 1286 1291 B-gender
with 6 10 1292 1296 O
pathologically 11 25 1297 1311 O
demonstrated 26 38 1312 1324 O
breast 39 45 1325 1331 B-cancer
cancer 46 52 1332 1338 I-cancer

studies 0 7 1339 1346 O
( 8 9 1347 1348 O
window 9 15 1348 1354 O
studies 16 23 1355 1362 O
, 23 24 1362 1363 O
for 25 28 1364 1367 O
example 29 36 1368 1375 O
) 36 37 1375 1376 O
that 38 42 1377 1381 O
are 43 46 1382 1385 O
deemed 47 53 1386 1392 O
non 54 57 1393 1396 O
- 57 58 1396 1397 O
therapeutic 58 69 1397 1408 O
, 69 70 1408 1409 O
including 71 80 1410 1419 O
those 81 86 1420 1425 O
that 87 91 1426 1430 O
utilize 92 99 1431 1438 O
agents 100 106 1439 1445 O
that 107 111 1446 1450 O
are 112 115 1451 1454 O
not 116 119 1455 1458 O
FDA 120 123 1459 1462 O
approved 124 132 1463 1471 O
for 133 136 1472 1475 O
the 137 140 1476 1479 O
treatment 141 150 1480 1489 O
of 151 153 1490 1492 O
the 154 157 1493 1496 O
patient 158 165 1497 1504 O
's 165 167 1504 1506 O
current 168 175 1507 1514 O
breast 176 182 1515 1521 B-cancer
cancer 183 189 1522 1528 I-cancer
, 189 190 1528 1529 O
are 191 194 1530 1533 O
permitted 195 204 1534 1543 O

